Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined. METHODS: We conducted a multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo. The primary end point was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined. RESULTS: After four weeks of treatment, the median level of low-density lipoprotein cholesterol was reduced by 42 percent among patients receiving atorvastatin, and among those receiving placebo it was reduced by 1.3 percent. During a median follow-up period of four years, 469 patients (37 percent) reached the primary end point, of whom 226 were assigned to atorvastatin and 243 to placebo (relative risk, 0.92; 95 percent confidence interval, 0.77 to 1.10; P=0.37). Atorvastatin had no significant effect on the individual components of the primary end point, except that the relative risk of fatal stroke among those receiving the drug was 2.03 (95 percent confidence interval, 1.05 to 3.93; P=0.04). Atorvastatin reduced the rate of all cardiac events combined (relative risk, 0.82; 95 percent confidence interval, 0.68 to 0.99; P=0.03, nominally significant) but not all cerebrovascular events combined (relative risk, 1.12; 95 percent confidence interval, 0.81 to 1.55; P=0.49) or total mortality (relative risk, 0.93; 95 percent confidence interval, 0.79 to 1.08; P=0.33). CONCLUSIONS: Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intensive glucose control (A1C levels <7% in T2D and <7.5% in T1D) in several clinical trials was found to reduce the risk of incident albuminuria (A2) and DKD onset.70,78,90,406–410”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“Finally, in the UKPDS, wherein intensive treatment led to a mean end point A1C of 7.0%, hypoglycemia occurred in 1.8% of insulin-treated persons per year in the intensive group vs 0.7% of conventionally treated persons per year.407”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“However, because of the gaps in data and negative study results, uncertainty exists over the benefits of applying proven CVD therapy in the general population to the CKD population, especially in patients with advanced kidney disease.”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia
Himmelfarb, J., Stenvinkel, P., Ikizler, T. A., & Hakim, R. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00600.x · Cited by 1,179
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- Takayama F, 1998, Cell Mol Biol, 44, 1101
Cited by
Items 901–1,000 of 1,004
Welten, G. M. J. M., Chonchol, M., Hoeks, S. E., Schouten, O., Dunkelgrün, M., van Gestel, Y. R. B. M., Goei, D., Bax, J. J., van Domburg, R. T., & Poldermans, D. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.06.040 · Cited by 30
Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
Schneider, A., Schneider, M. P., Scharnagl, H., Jardine, A. G., Wanner, C., & Drechsler, C. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-67 · Cited by 30
Self-citationBesong, S. A., Ezekwe, M. O., & Ezekwe, E. I. (2011) · International Journal of Nutrition and Metabolism · doi:10.5897/ijnam.9000013 · Cited by 36
Metabolic syndrome in peritoneal dialysis patients
Li, P. K.-T., Kwan, B. C., Szeto, C., & Ko, G. T. C. (2008) · Clinical Kidney Journal · doi:10.1093/ndtplus/sfn073 · Cited by 30
Pitt, B., & Rossignol, P. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.057 · Cited by 28
The Cardiorenal Syndrome: What the Cardiologist Needs to Know
Waldum, B., & Os, I. (2013) · Cardiology · doi:10.1159/000353261 · Cited by 31
Olyaei, A. J., Greer, E., Santos, R. D., & Rueda, J. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09091010 · Cited by 27
Saglimbene, V. M., Wong, G., Ruospo, M., Palmer, S. C., Campbell, K. L., García-Larsen, V., Natale, P., Teixeira-Pinto, A. M., Carrero, J. J., Stenvinkel, P., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.11.020 · Cited by 27
COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors
Podestà, M. A., Valli, F., Galassi, A., Cassia, M. A., Ciceri, P., Barbieri, L., Carugo, S., & Cozzolino, M. G. (2021) · Blood Purification · doi:10.1159/000514467 · Cited by 29
Association of Serum Phosphate with Efficacy of Statin Therapy in Hemodialysis Patients
Massy, Z. A., Merkling, T., Wagner, S., Girerd, N., Essig, M., Wanner, C., Fellstrom, B. C., Rossignol, P., & Zannad, F. M. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12620921 · Cited by 27
Self-citationPhysical Activity and Exercise for Cardiorespiratory Health and Fitness in Chronic Kidney Disease
Gollie, J. M., Cohen, S. D., & Patel, S. S. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2308273 · Cited by 27
Diabetes-related end-stage renal disease in Austria 1965–2013
Prischl, F. C., Auinger, M., Säemann, M. D., Mayer, G. J., Rosenkranz, A. R., Wallner, M., & Kramar, R. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv113 · Cited by 27
Dyslipidemia in Chronic Kidney Disease: Managing a High-Risk Combination
Chauhan, V., & Vaid, M. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2077 · Cited by 28
Novedades en hipertensión arterial y diabetes mellitus
Cordero, A., Fácila, L., Galve, E., & Mazón, P. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70144-5 · Cited by 30
AGEs and Cardiovascular Diseases in Patients With End-Stage Renal Diseases
Nishizawà, Y., Koyama, H., & Inaba, M. (2011) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2011.10.019 · Cited by 27
The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups
Catapano, A. L., Toth, P. P., Tomassini, J. E., & Tershakovec, A. M. (2013) · Clinical Lipidology · doi:10.2217/clp.12.88 · Cited by 28
Locatelli, F., Dimkovic, N. B., & Spasovski, G. B. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft064 · Cited by 27
Pauriah, M., Elder, D. H. J., Ogston, S. A., Noman, A., Majeed, A., Wyatt, J. C., Choy, A. M., MacDonald, T. M., Struthers, A. D., & Lang, C. C. (2014) · Heart · doi:10.1136/heartjnl-2013-304678 · Cited by 28
Monitoring of hemodialysis quality-of-care indicators: why is it important?
Grangé, S., Hanoy, M., Roy, F. L., Guerrot, D., & Godin, M. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-109 · Cited by 27
Minimized Weight Gain between Hemodialysis Contributes to a Reduced Risk of Death
Stegmayr, B. G., Brännström, M., Bucht, S., Dimény, E., Ekspong, A., Granroth, B., Gröntoft, K., Hadimeri, H., Holmberg, B., Ingman, B., et al. (2006) · The International Journal of Artificial Organs · doi:10.1177/039139880602900705 · Cited by 27
Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke
Fletcher, G. F., Bufalino, V. J., Costa, F., Goldstein, L. B., Jones, D., Smaha, L. A., Smith, S. C., & Stone, N. J. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.02.001 · Cited by 29
Vascular calcification—a matter of damage limitation?
Shanahan, C. M. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl089 · Cited by 27
Preventive health care in chronic kidney disease and end-stage renal disease
Choudhury, D., & Luna-Salazar, C. (2008) · Nature Reviews Nephrology · doi:10.1038/ncpneph0762 · Cited by 27
White, C. A., Jaffey, J., & Magner, P. O. C. (2006) · Kidney International · doi:10.1038/sj.ki.5002037 · Cited by 27
Prognosis of patients with peripheral arterial disease.
Welten, G. M. J. M., Schouten, O., Chonchol, M., Hoeks, S. E., Bax, J. J., van Domburg, R. T., & Poldermans, D. (2009) · PubMed · Cited by 34
Cardiovascular Risk and Its Presentation in Chronic Kidney Disease
Schunk, S. J., & Zimmermann, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134567 · Cited by 31
Chung, C., Lin, M., Hsu, J., Hsiao, J., Chang, S., Pan, K., Lin, C., & Lin, Y. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.01.001 · Cited by 26
Dyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 30
Schneider, M. P., Hübner, S., Titze, S. I., Schmid, M. C., Nadal, J., Schlieper, G., Busch, M., Baid‐Agrawal, S., Krane, V., Wanner, C., et al. (2015) · Kidney International · doi:10.1038/ki.2015.246 · Cited by 27
Self-citationArtunç, F., Nowak, A., Mueller, C. E., Peter, A., Heyne, N., Häring, H., & Friedrich, B. (2014) · Kidney & Blood Pressure Research · doi:10.1159/000368468 · Cited by 26
Diabetes, Cardiovascular Risk and Nephropathy
Hahr, A. J., & Molitch, M. E. (2010) · Cardiology Clinics · doi:10.1016/j.ccl.2010.04.006 · Cited by 29
Dunlop, J. L., Vandal, A. C., de Zoysa, J., Gabriel, R. S., Haloob, I. A., Hood, C. J., Matheson, P. J., McGregor, D., Rabindranath, K. S., Semple, D. J., et al. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-149 · Cited by 27
Franch, H. A., & Mitch, W. E. (2009) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-080508-141051 · Cited by 28
Kirsch, A. H., Kirsch, A., Artinger, K., Schabhüttl, C., Goessler, W., Klymiuk, I., Gülly, C., Fritz, G. A., Frank, S., Wimmer, R., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv265 · Cited by 26
Han, S. H., Kang, E. W., Yoon, S., Yoon, H. S., Lee, H. C., Yoo, T., Choi, K. H., Han, D.-I., & Kang, S. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr108 · Cited by 26
ESRD ‐induced dyslipidemia—Should management of lipid disorders differ in dialysis patients?
Moradi, H., Streja, E., & Vaziri, N. D. (2018) · Seminars in Dialysis · doi:10.1111/sdi.12706 · Cited by 26
Herrera‐Gómez, F., Chimeno, M. M., Martín-García, D., Lizaraso-Soto, F., Maurtua-Briseño-Meiggs, Á., Grande-Villoría, J., Bustamante‐Munguira, J., Alamartine, É., Vilardell, M., Sangrador, C. O., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45431-5 · Cited by 26
Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease
Johnston, N., Dargie, H. J., & Jardine, A. G. (2008) · Heart · doi:10.1136/hrt.2007.136739 · Cited by 26
Disorders in High-Density Metabolism With Insulin Resistance and Chronic Kidney Disease
Kaysen, G. A. (2007) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2006.10.002 · Cited by 27
Sepanlou, S. G., Mann, J. F. E., Joseph, P. G., Pais, P. S., Gao, P., Sharafkhah, M., Roshandel, G., Yusuf, S., & Malekzadeh, R. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000251 · Cited by 29
Self-citationDesign of the Blood Pressure Goals in Dialysis Pilot Study
Gul, A., Harford, A., Horowitz, B., Bedrick, E. J., Miskulin, D. C., Gassman, J., Chen, J. L. T., Paine, S., Kusek, J. W., Unruh, M. L., et al. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31827daee5 · Cited by 27
de Francisco, Á. L. M., Kim, J. D., Anker, S. D., Belozeroff, V., Canaud, B., Chazot, C., Drüeke, T. B., Eckardt, K., Floege, J., Kronenberg, F., et al. (2010) · Nephron Clinical Practice · doi:10.1159/000319936 · Cited by 25
Clinical trials in end-stage renal disease—priorities and challenges
Kovesdy, C. P. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz088 · Cited by 25
Cheng, Y., Qiao, L., Jiang, Z., Dong, X., Feng, H., Gui, Q., Lu, Y., & Liang, Y. (2020) · PubMed · Cited by 33
High-Density Lipoproteins in Kidney Disease
Kon, V., Yang, H., Smith, L. E., Vickers, K. C., & Linton, M. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158201 · Cited by 28
Herzog, C. A. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn637 · Cited by 26
Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?
Rossini, E., Biscetti, F., Rando, M. M., Nardella, E., Cecchini, A. L., Nicolazzi, M. A., Covino, M., Gasbarrini, A., Massetti, M., & Flex, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169326 · Cited by 31
Ennezat, P. V., Guerbaaï, R.-A., Maréchaux, S., Jemtel, T. H. L., & François, P. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001345 · Cited by 25
Pauly, R. P., & Chan, C. T. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00344.x · Cited by 26
Statins: a preventive strike against sepsis in patients with cardiovascular disease?
Merx, M. W., & Weber, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68042-2 · Cited by 25
Miller, L., Sood, M. M., Sood, A. R., Reslerova, M., Komenda, P. V. J., Rigatto, C., & Bueti, J. (2010) · International Urology and Nephrology · doi:10.1007/s11255-010-9857-x · Cited by 26
Kuo, C., Hsieh, T., Wang, C., Chou, C., Lai, Y., Chen, Y.-Y., Lin, Y., Wu, S.-T., & Fang, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121705 · Cited by 25
Baggetta, R., Bolignano, D., Torino, C., Manfredini, F., Aucella, F., Barillà, A., Battaglia, Y., Bertoli, S. V., Bonanno, G., Castellino, P., et al. (2014) · Kidney & Blood Pressure Research · doi:10.1159/000355797 · Cited by 25
The role of echocardiographic study in patients with chronic kidney disease
Liu, Y.-W., Su, C.-T., Song, E.-J., Tsai, W., Li, Y., Tsai, L.-M., Chen, J.-H., & Sung, J. (2015) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2015.06.009 · Cited by 25
Athyros, V. G., Mitsiou, E. K., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903575654 · Cited by 25
Herrington, W. G., Emberson, J., Staplin, N., Blackwell, L. S., Fellström, B., Walker, R. J., Levin, A., Hooi, L. S., Massy, Z. A., Tesař, V., et al. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10371013 · Cited by 25
Lee, J. E., Oh, K.-H., Choi, K. H., Kim, S. B., Kim, Y. S., Do, J.-Y., Kim, Y.-L., & Kim, D. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr229 · Cited by 25
Lowering cholesterol in chronic kidney disease: is it safe and effective?
Wong, M. G., Wanner, C., Knight, J. F., & Perkovic, V. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv393 · Cited by 28
Self-citationSu, H.-H., Kao, C.-M., Lin, Y.-C., Lin, Y.-C., Kao, C., Chen, H.-H., Hsu, C.-C., Chen, K., Peng, C.-C., & Wu, M.-S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.09.001 · Cited by 25
Hung, A. M., Tsuchida, Y., Nowak, K. L., Sarkar, S., Chonchol, M., Whitfield, V., Salas, N., Dikalova, A., Yancey, P. G., Huang, J., et al. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04360418 · Cited by 25
Khor, B., Tallman, D. A., Karupaiah, T., Khosla, P., Chan, M., & Kopple, J. D. (2021) · Nutrients · doi:10.3390/nu13103341 · Cited by 25
Health‐related quality of life in the era of erythropoietin
Weisbord, S. D., & Kimmel, P. L. (2008) · Hemodialysis International · doi:10.1111/j.1542-4758.2008.00233.x · Cited by 25
Management of hyperlipidemia in patients on peritoneal dialysis: Current approaches
Prichard, S. S. (2006) · Kidney International · doi:10.1038/sj.ki.5001926 · Cited by 25
Baber, U., Toto, R. D., & de Lemos, J. A. (2007) · American Heart Journal · doi:10.1016/j.ahj.2006.10.042 · Cited by 25
Abidor, E., Achkar, M. A., Saidi, I. A., Lather, T., Jdaidani, J., Agarwal, A., & El‐Sayegh, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020643 · Cited by 26
Lipid Disorders in Uremia and Dialysis
Bakris, G. L. (2012) · Contributions to nephrology · doi:10.1159/000337821 · Cited by 24
The ezetimibe Jonah: the trials and tribulations of an unlucky drug
Wierzbicki, A. S. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02789.x · Cited by 24
Ridker, P. M., Rose, L. M., & Cook, N. R. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.12.028 · Cited by 25
Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes
Matikainen, N., & Taskinen, M. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0309-3 · Cited by 27
Kostis, J. B., Giakoumis, M., Zinonos, S., Cabrera, J., & Kostis, W. J. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.01.020 · Cited by 25
Wei, X., Wen, Y., Zhou, Q., Feng, X., Peng, F. F., Wang, N., Wang, X., & Wu, X. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01405-5 · Cited by 24
Lo, H.-Y., Lin, Y., Lin, D. S., Lee, J., & Chen, W. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.29706 · Cited by 25
Coronary Artery Calcium Scanning Should be Used for Primary Prevention
Nasir, K., Shaw, L. J., Budoff, M. J., Ridker, P. M., & Peña, J. M. (2012) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2011.11.007 · Cited by 24
Acute coronary syndrome in ESRD patients
Surana, S. P., Riella, L. V., Keithi-Reddy, S. R., Charytan, D. M., & Singh, A. K. (2008) · Kidney International · doi:10.1038/ki.2008.233 · Cited by 26
Hooper, D. K., Williams, J. C., Carle, A. C., Amaral, S. G., Chand, D. H., Ferris, M., Patel, H. P., Licht, C. P. B., Barletta, G., Zitterman, V., et al. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2419-6 · Cited by 25
Cardiorenal Syndrome Type 4: Management
Clementi, A., Virzì, G. M., Brocca, A., de Cal, M., Vescovo, G., Granata, A. R. M., & Ronco, C. (2013) · Blood Purification · doi:10.1159/000356369 · Cited by 24
Tentzeris, I., Rohla, M., Járai, R., Farhan, S., Freynhofer, M. K., Unger, G., Nürnberg, M., Geppert, A., Wessely, E., Wojta, J., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.12.012 · Cited by 27
Hammer, F., Krane, V., Störk, S., Roser, C., Hofmann, K. B., Pollak, N., Allolio, B., & Wanner, C. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft409 · Cited by 24
Self-citationLocatelli, F., Dimkovic, N. B., Pontoriero, G., Spasovski, G. B., Plješa, S., Kostić, S., Manning, A., Sano, H., & Nakajima, S. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp445 · Cited by 24
Yuen, D. A., Kuliszewski, M. A., Liao, C., Rudenko, D., Leong-Poi, H. M., & Chan, C. T. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10911210 · Cited by 24
Umemoto, N., Ishii, H., Kamoi, D., Aoyama, T., Sakakibara, T., Takahashi, H., Tanaka, A., Yasuda, Y., Suzuki, S., Matsubara, T., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.037 · Cited by 24
Vascular calcification: When should we interfere in chronic kidney disease patients and how?
Din, U. A. S. E., Salem, M. M., & Abdulazim, D. O. (2016) · World Journal of Nephrology · doi:10.5527/wjn.v5.i5.398 · Cited by 27
What Happens to the Heart in Chronic Kidney Disease?
Rutherford, E., & Mark, P. B. (2017) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2017.117 · Cited by 24
Cardiovascular Outcomes Reported in Hemodialysis Trials
O’Lone, E., Viecelli, A. K., Craig, J. C., Tong, A., Sautenet, B., Roy, D. A., Herrington, W. G., Herzog, C. A., Jafar, T. H., Jardine, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.012 · Cited by 28
Self-citationStatins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation
Obialo, C. I., Ofili, E., & Norris, K. C. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15122733 · Cited by 24
Alsayed, N., Almahmeed, W. A., Alnouri, F., Al-Waili, K., Sabbour, H. M., Sulaiman, K., Zubaid, M., Ray, K. K., & Al‐Rasadi, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.022 · Cited by 25
Scarpioni, R., Ricardi, M., Melfa, L., & Cristinelli, L. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00182.x · Cited by 26
Dyslipidemia in chronic kidney disease: pathogenesis and intervention
Piecha, G., Adamczak, M., & Ritz, E. (2009) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.745 · Cited by 24
Self-citationInfluence of CD4+/CD25+regulatory T cells on atherogenesis in patients with end-stage kidney disease
Meier, P., Meier, R., & Blanc, E. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.7.987 · Cited by 29
Preventing microalbuminuria in patients with type 2 diabetes
Jermendy, G., & Ruggenenti, P. L. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.693 · Cited by 32
Cleland, J. G. F., Coletta, A. P., Abdellah, A. T., Cullington, D., Clark, A. L., & Rigby, A. S. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2007.12.004 · Cited by 24
Walsh, M. W., Manns, B., Klarenbach, S. W., Quinn, R. R., Tonelli, M. A., & Culleton, B. F. (2006) · BMC Nephrology · doi:10.1186/1471-2369-7-2 · Cited by 24
How to Decrease Cardiovascular Mortality in Renal Transplant Recipients
Ostovan, M. A., Fazelzadeh, A., Mehdizadeh, A., Razmkon, A., & Malek‐Hosseini, S. A. (2006) · Transplantation Proceedings · doi:10.1016/j.transproceed.2006.08.091 · Cited by 24
Paraskevas, K. I., Kotsikoris, I., Koupidis, S. A., Tzovaras, A. A., & Mikhailidis, D. P. (2010) · International Urology and Nephrology · doi:10.1007/s11255-010-9795-7 · Cited by 24
The Causal-Benefit Model to Prevent Cardiovascular Events
Kohli-Lynch, C. N., Thanassoulis, G., Pencina, M. J., Sehayek, D., Pencina, K. M., Moran, A. E., & Sniderman, A. D. (2024) · JACC Advances · doi:10.1016/j.jacadv.2023.100825 · Cited by 23
Statins and noncardiac vascular disease
Paraskevas, K. I., Wierzbicki, A. S., & Mikhailidis, D. P. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328353add9 · Cited by 24
Effect of atorvastatin on testosterone levels
Shawish, M. I., Bagheri, B., Musini, V. M., Adams, S. P., & Wright, J. M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013211.pub2 · Cited by 27
Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy
Tsioufis, K. P., Castellano, J. M., Sykara, G. D., Malvestiti, F. M., & van Vugt, J. (2021) · Cardiology and Therapy · doi:10.1007/s40119-021-00240-8 · Cited by 23
Iyngkaran, P., Majoni, W., Cass, A., Sanders, P., Ronco, C., Brady, S., Kangaharan, N., Ilton, M. K., Hare, D. L., & Thomas, M. C. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.12.007 · Cited by 26
Fukushima, M., Miura, S., Mitsutake, R., Fukushima, T., Fukushima, K., & Saku, K. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1302 · Cited by 28
Metadata
- Authors
- Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E.
- Affiliations
- University of Würzburg (DE)
- Medical University of Graz (AT)
- University Medical Center Freiburg (DE)
- München Klinik Schwabing (DE)
- Pfizer (Germany) (DE)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-07-21
- Volume
- 353
- Issue
- 3
- Pages
- 238-248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110601215
- Cited by
- 2,614
- References
- 30
- Citations by year
- 2026: 74 · 2025: 51 · 2024: 66 · 2023: 76 · 2022: 90 · 2021: 92 · 2020: 97 · 2019: 110 · 2018: 96 · 2017: 104 · 2016: 110 · 2015: 132 · 2014: 153 · 2013: 162 · 2012: 185
- FWCI
- 135.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- atorvastatin, type 2 diabetes, hemodialysis, statins, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, LDL cholesterol, end-stage renal disease
- MeSH terms
- Atorvastatin, Aged, Cerebrovascular Disorders, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Diseases, Renal Dialysis, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Pyrroles, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.